GENOA - The multinational Pfizer-Biontech has chosen Genoa, the only city in Italy, for a study on anti-covid vaccines.
Three countries are involved, 20 research centers among which the only Italian is the one directed by Professor Giancarlo Icardi, director of the Hygiene Department of the San Martino Polyclinic.
The survey, as reported by the local edition of Repubblica, will involve 13,000 people around the world.
150 volunteers have already joined in Genoa.
In practice, those participating in the research will have to respond to some tests on the state of health within two years after the administration of the two doses of vaccine.
Questionnaires will initially be distributed at weeks one, two, four, six and eight after the first and second doses and then every three months until the study is completed.
Those who participate in the project will receive a total remuneration of 171 euros.
"The purpose of this study - explained Icardi - is to acquire more information on the effects of Cominarty in the context of the real world. It is a very important study because it is observational4 and is coordinated by the Istituto Superiore di Sanità".
Unlike passive surveillance "this study - continues the professor - consists of active surveillance, in which the subject is also invited to report any event he notices, both those that are foreseeable side effects, already reported in the vaccine data sheet, or any other symptom ".
At the end of the study, the data will be analyzed to isolate any actual connections between manifestations and administration of the vaccine.
(HANDLE).
